Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More
Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More
AUROBINDO PHARMA | PROCTER & GAMBLE HEALTH | AUROBINDO PHARMA/ PROCTER & GAMBLE HEALTH |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 18.1 | 62.3 | 29.0% | View Chart |
P/BV | x | 3.9 | 7.7 | 51.0% | View Chart |
Dividend Yield | % | 0.3 | 6.2 | 4.4% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
AUROBINDO PHARMA Mar-19 |
PROCTER & GAMBLE HEALTH Dec-18 |
AUROBINDO PHARMA/ PROCTER & GAMBLE HEALTH |
5-Yr Chart Click to enlarge
|
||
High | Rs | 830 | 3,549 | 23.4% | |
Low | Rs | 527 | 1,301 | 40.5% | |
Sales per share (Unadj.) | Rs | 333.9 | 511.4 | 65.3% | |
Earnings per share (Unadj.) | Rs | 40.4 | 61.3 | 65.8% | |
Cash flow per share (Unadj.) | Rs | 51.8 | 74.0 | 69.9% | |
Dividends per share (Unadj.) | Rs | 2.50 | 440.00 | 0.6% | |
Dividend yield (eoy) | % | 0.4 | 18.1 | 2.0% | |
Book value per share (Unadj.) | Rs | 237.1 | 927.8 | 25.6% | |
Shares outstanding (eoy) | m | 585.91 | 16.60 | 3,529.6% | |
Bonus/Rights/Conversions | ESOP | - | - | ||
Price / Sales ratio | x | 2.0 | 4.7 | 42.9% | |
Avg P/E ratio | x | 16.8 | 39.6 | 42.5% | |
P/CF ratio (eoy) | x | 13.1 | 32.8 | 40.0% | |
Price / Book Value ratio | x | 2.9 | 2.6 | 109.5% | |
Dividend payout | % | 6.2 | 717.9 | 0.9% | |
Avg Mkt Cap | Rs m | 397,569 | 40,257 | 987.6% | |
No. of employees | `000 | 17.9 | 1.1 | 1,574.5% | |
Total wages/salary | Rs m | 25,849 | 1,313 | 1,969.1% | |
Avg. sales/employee | Rs Th | 10,956.9 | 7,486.7 | 146.4% | |
Avg. wages/employee | Rs Th | 1,447.7 | 1,157.6 | 125.1% | |
Avg. net profit/employee | Rs Th | 1,324.3 | 897.2 | 147.6% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 195,636 | 8,490 | 2,304.3% | |
Other income | Rs m | 1,553 | 244 | 636.8% | |
Total revenues | Rs m | 197,189 | 8,734 | 2,257.8% | |
Gross profit | Rs m | 39,519 | 1,482 | 2,667.3% | |
Depreciation | Rs m | 6,680 | 211 | 3,162.6% | |
Interest | Rs m | 2,626 | 0 | - | |
Profit before tax | Rs m | 31,767 | 1,514 | 2,097.8% | |
Minority Interest | Rs m | 27 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | -881 | 66 | -1,342.4% | |
Tax | Rs m | 7,269 | 563 | 1,292.2% | |
Profit after tax | Rs m | 23,645 | 1,017 | 2,324.1% | |
Gross profit margin | % | 20.2 | 17.5 | 115.8% | |
Effective tax rate | % | 22.9 | 37.1 | 61.6% | |
Net profit margin | % | 12.1 | 12.0 | 100.9% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 153,645 | 15,343 | 1,001.4% | |
Current liabilities | Rs m | 120,429 | 1,960 | 6,143.7% | |
Net working cap to sales | % | 17.0 | 157.6 | 10.8% | |
Current ratio | x | 1.3 | 7.8 | 16.3% | |
Inventory Days | Days | 135 | 49 | 277.4% | |
Debtors Days | Days | 64 | 28 | 223.9% | |
Net fixed assets | Rs m | 103,909 | 1,209 | 8,592.5% | |
Share capital | Rs m | 586 | 166 | 353.0% | |
"Free" reserves | Rs m | 138,322 | 15,235 | 907.9% | |
Net worth | Rs m | 138,908 | 15,401 | 901.9% | |
Long term debt | Rs m | 1,800 | 0 | - | |
Total assets | Rs m | 264,544 | 17,595 | 1,503.6% | |
Interest coverage | x | 13.1 | NM | - | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 0.7 | 0.5 | 153.3% | |
Return on assets | % | 9.9 | 5.8 | 171.7% | |
Return on equity | % | 17.0 | 6.6 | 257.7% | |
Return on capital | % | 23.8 | 10.3 | 232.4% | |
Exports to sales | % | 49.6 | 0 | - | |
Imports to sales | % | 18.8 | 0 | - | |
Exports (fob) | Rs m | 97,091 | NA | - | |
Imports (cif) | Rs m | 36,741 | NA | - | |
Fx inflow | Rs m | 97,316 | 1,636 | 5,947.3% | |
Fx outflow | Rs m | 40,589 | 4,368 | 929.2% | |
Net fx | Rs m | 56,727 | -2,732 | -2,076.6% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 16,220 | -1,304 | -1,244.1% | |
From Investments | Rs m | -28,768 | 12,697 | -226.6% | |
From Financial Activity | Rs m | 19,191 | -301 | -6,386.2% | |
Net Cashflow | Rs m | 6,656 | 11,093 | 60.0% |
Indian Promoters | % | 54.1 | 0.0 | - | |
Foreign collaborators | % | 0.0 | 51.8 | - | |
Indian inst/Mut Fund | % | 8.0 | 18.2 | 43.7% | |
FIIs | % | 27.7 | 1.0 | 2,770.0% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 10.2 | 29.1 | 35.1% | |
Shareholders | 69,601 | 28,591 | 243.4% | ||
Pledged promoter(s) holding | % | 8.6 | 0.0 | - |
Compare AUROBINDO PHARMA With: CADILA HEALTHCARE TTK HEALTHCARE SHASUN PHARMA DISHMAN PHARMA J.B.CHEMICALS
Compare AUROBINDO PHARMA With: ACTAVIS (US) MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Asian share markets rose for the third straight session today, tracking gains in US peers. The Nikkei is trading up by 0.7% and the Hang Seng is trading up by 0.1%.
For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
For the quarter ended June 2020, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 692 m (up 57.0% YoY). Sales on the other hand came in at Rs 6 bn (up 171.6% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.
For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
More Views on NewsThe smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.
The charts are telling the bulls to be cautious.
Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
Our ace stock picker is ready to capitalise on a big growth opportunity.
More